IRIS

In progress

Today, the therapeutic management of patients with melanoma is a major challenge. Indeed, the latter is growing faster than all other cancers, especially in the young population. For the low impact of this therapies to toxicology, under add the toxicology. Of these, vaccines used dendritic cells (DCs) are generated ex-vivo from autologous CDs. They must be made to measure for each patient. This procedure is laborious and expensive, preventing the generalization of this immunotherapy. The in-vivo release of immunostimulatory molecules. In this context, we propose a therapeutic approach to the local delivery of a plasmid encoding interleukin-12, by ultrasound guided sonoporation (US). To achieve this goal, a new US probe will be developed and presented. The effectiveness of this therapy will be tested on a model of melanoma by imaging and by the analysis of the immune response. The purpose of the project is to make available to oncologists, this new therapeutic arsenal.

Project benefits

There are no benefits for this project at this time

People involved in the project

Member partner

No member partner

CENTRE SCIENCES

Groupe Innovation et ciblage cellulaire (GICC)

Strategic business lines

Smart power grids


Referent of the project

Nicolas POUSSET
Responsable Technique

07 86 53 38 70

nicolas.pousset-s2e2-ext@st.com

Centre val de loire

These projects may be of interest to you

Back to the projects